To our MarketingRx readers —
Last week, we made the decision to shut down Endpoints MarketingRx. Over the last year, Endpoints News has put more resources into our core biopharma and healthcare coverage, and into work where we’re seeing the most significant reader interest and support.
We’ll continue to cover commercial competition and strategy — in fact, we’re adding resources to do so — but as a part of a broader story about how drug products are sold. If you haven’t already, I’d encourage you to sign up for our main Endpoints newsletter or our pharma report covering commercial and regulatory issues. You can click here to update your subscription preferences.
Thank you for reading us over the years. And I’d like to extend a special thank you to Senior Editor Beth Snyder Bulik, who tirelessly led MarketingRx and who many of you have grown used to seeing in your inbox each Tuesday. As part of this change, Beth has left Endpoints, and we’re thankful for our time working with such a careful and thoughtful journalist.
-Drew Armstrong, Executive Editor